Financing ·
OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing $125 million in…
OPKOpko Health, Inc.
OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing $125 million in additional senior secured notes maturing July 17, 2044. Interest accrues at SOFR plus 7.5% with a 4.0% floor and is payable quarterly using profit share payments from EirGen Pharma’s Pfizer arrangement for mazdutide sales in China. If those royalties are insufficient, interest is paid from Mazdutide Payments secured by an Eli Lilly license, capped at $187.5 million, with any excess applied to principal reduction. The company operates in the biotechnology and healthcare diagnostics industry.